Literature DB >> 32458237

Good response to mycophenolate mofetil on treatment of interstitial lung disease in polymyositis associated with antisynthetase syndrome positive for anti-EJ and anti-Ro52 antibodies.

Erika A Martínez-García1,2,3, Andrea V Lujano-Benítez1, Ignacio García-De La Torre3,4, Mónica Vázquez-Del Mercado5,6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32458237     DOI： 10.1007/s10067-020-05075-7

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  7 in total

1.  Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis.

Authors:  Thomas Barba; Romain Fort; Vincent Cottin; Steeve Provencher; Isabelle Durieu; Sabine Jardel; Arnaud Hot; Quitterie Reynaud; Jean-Christophe Lega
Journal:  Autoimmun Rev       Date:  2018-12-17       Impact factor: 9.754

2.  Heterogeneous clinical spectrum of interstitial lung disease in patients with anti-EJ anti-synthetase syndrome: a case series.

Authors:  Margherita Giannini; Antonella Notarnicola; Maryam Dastmalchi; Ingrid E Lundberg; Giuseppe Lopalco; Florenzo Iannone
Journal:  Clin Rheumatol       Date:  2016-04-11       Impact factor: 2.980

3.  Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis.

Authors:  Ejaz A Shamim; Lisa G Rider; Janardan P Pandey; Terrance P O'Hanlon; Luis J Jara; Eduardo A Samayoa; Ruben Burgos-Vargas; Janitzia Vazquez-Mellado; Jorge Alcocer-Varela; Mario Salazar-Paramo; Abraham Garcia Kutzbach; James D Malley; Ira N Targoff; Ignacio Garcia-De la Torre; Frederick W Miller
Journal:  Arthritis Rheum       Date:  2002-07

4.  Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.

Authors:  Jutta Bauhammer; Norbert Blank; Regina Max; Hanns-Martin Lorenz; Ulrich Wagner; Dietmar Krause; Christoph Fiehn
Journal:  J Rheumatol       Date:  2016-06-01       Impact factor: 4.666

Review 5.  Interstitial lung disease associated with systemic sclerosis (SSc-ILD).

Authors:  Vincent Cottin; Kevin K Brown
Journal:  Respir Res       Date:  2019-01-18

6.  Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara.

Authors:  Marcelo H Petri; Minoru Satoh; Beatriz T Martin-Marquez; Raul Vargas-Ramírez; Luis J Jara; Miguel A Saavedra; Claudia Cruz-Gonzalez; Lilia Andrade-Ortega; Olga Vera-Lastra; Mario Salazar-Páramo; Rosa E Prieto-Parra; Laura Gonzalez-Lopez; Jorge I Gamez-Nava; Hermes U Ramírez-Sánchez; Jason Y F Chan; Steven J Ross; Edward K L Chan; Mónica Vázquez-Del Mercado
Journal:  Arthritis Res Ther       Date:  2013-04-04       Impact factor: 5.156

7.  Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group.

Authors:  Sabine Adler; Dörte Huscher; Elise Siegert; Yannick Allanore; László Czirják; Francesco DelGaldo; Christopher P Denton; Oliver Distler; Marc Frerix; Marco Matucci-Cerinic; Ulf Mueller-Ladner; Ingo-Helmut Tarner; Gabriele Valentini; Ulrich A Walker; Peter M Villiger; Gabriela Riemekasten
Journal:  Arthritis Res Ther       Date:  2018-01-30       Impact factor: 5.156
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.